Metropolis Healthcare Ltd.
Snapshot View

3002.35 +8.30 ▲0.3%

05 August 2021, 04:00:00 P.M.
Volume: 27,533

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Hospital & Healthcare Services Compare with Industry peers
Website http://www.metropolisindia.com
Financial Indicators
Market Cap 15,315.86 Cr.
Earnings per share (EPS) 35.79 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 83.65 Trailing Twelve Months Ending 2021-03
Industry PE 202.10 Trailing Twelve Months Ending 2021-03
Book Value / Share 136.63 Trailing Twelve Months Ending 2021-03
Price to Book Value 21.91 Calculated using Price: 2,994.05
Dividend Yield 0.27 Period Ending 2021-03
No. of Shares Subscribed 5.12 Cr. 51,154,329 Shares
FaceValue 2
Company Profile

Metropolis Healthcare Limited is one of leading and renowned Indian diagnostics companies. The company owns a chain of diagnostic ce9ntres across India, South Asia, Africa and the Middle East. Over the years, Metropolis has carved a niche for itself. The company enjoys a loyal customer base, reflecting its strength as a brand offering superior diagnostic tests and services.

With its widespread operational network, Metropolis offers a comprehensive range of clinical laboratory tests and profiles. These tests and profiles are used for prediction, early detection, diagnostic screening, confirmation and/or monitoring of the disease. Metropolis plays a pivotal role in raising the bar of diagnostic accuracy, technological equipment, customer experience and research-driven empathetic service in the industry.

Business area of the company

Metropolis Healthcare is engaged in the business of providing pathology and related healthcare services. The profile comprises of a variety of test combinations which are specific to a disease or disorder as well as wellness profiles that are used for health and fitness screening. It classifies its tests into ‘routine’ tests such as blood chemistry analyses, blood cell counts and urine examination; ‘semi-specialized’ tests such as thyroid function tests, viral and bacterial cultures, histology, cytology and infectious disease tests; and ‘specialized’ tests such as tests for coagulation studies, autoimmunity tests, cytogenetics and molecular diagnostics. It is focused on providing reliable test results as well as value-added services such as home collection of specimens and online access to test reports. It also offers customized wellness packages to its institutional customers as per their requirement.

Services

  • Pathology Testing Services
  • Corporate Wellness
  • Lab in Hospitals
  • Clinical Research Services

Awards

FY2018-19

  • The Global Reference Laboratory of Metropolis holds accreditation from the College of American Pathologists (CAP) since 2005 which is the gold standard in accreditations in industry, globally.
  • Metropolis Healthcare was awarded Iconic Pathology Lab Award by Mid-Day Health & Wellness Awards in September 2018
  • Metropolis received the ‘Best Diagnostic Laboratory’ in India award at the Women’s Health Conference 2019
  • Metropolis was awarded special jury mention for “Service Excellence (Diagnostic Centre)” by FICCI at the Healthcare Excellence Awards 2018
  • Metropolis Healthcare won the Best Temperature Controlled Project of the year at the Cold Chain Summit Awards held in Mumbai, 2018
  • Metropolis Healthcare honored for Excellence in Customer Service & Delivery at the Home Healthcare Summit & Awards 2018
  • Company was awarded for “Best in Health and Fitness” in the Digital Campaign Awards by LH Insights 2018.

FY2019-20

  • Accorded as the Most Admired Healthcare Company of The Year - February 2020
  • Won the award for Best It Practices at the Data Center Summit 2019 - October 2019
  • Awarded as the Best Patient Experience Team Of The Year Award at PEXA Awards 2019, in Delhi - December 2019
  • Won the Healthcare Leadership Award, at the Uttar Pradesh Healthcare Leadership Awards 2019 held at Lucknow - October 2019
  • Bagged Excellence In Logistics award at the CII SCALE Awards 2019 - Supply Chain & Logistics Excellence Awards organised by Confederation of Indian Industries - December 2019
  • Awarded the Best It Enabled Pathology Chain Award during the 4th Digital Innovation Health Summit and CIO Awards at Kolkata
  • Won a special mention as the Best Performance-Driven Digital Campaign Award at the InkSpell Drivers of Digital Awards 2019 - December 2019
  • Conferred the Best Logistics Network Optimization & Best Use Of Technology In Logistics awards announced at the 5th Asian Supply Chain Thought Leadership Summit & Awards in Mumbai - November 2019

Major Events & Milestones

  • 2002: First major acquisition by company of Sudharma.
  • 2004: The company was accredited by National Accreditation Board for Testing and Calibration Laboratories (Department of Science & Technology, India).
  • 2005: The company received accreditation from The College of American Pathologists.
  • 2006: Investment by The Western India Trustee and Executor company in company.
  • 2006: Acquisition of Lister Laboratory and Research Centre Private Limited in Chennai.
  • 2007: Acquisition of Desai Clinical Laboratory in Surat.
  • 2008: Acquisition of R.V Diagnostics & Healthcare Center Private Limited in Bangalore.
  • 2010: Investment by Foxcreek Investment Limited in company.
  • 2012: Acquisition of Micron Laboratories in Mumbai.
  • 2012: Incorporation of subsidiary in Mauritius.
  • 2013: Establishment of GRL in Mumbai.
  • 2014: Acquisition of subsidiary in Ghana.
  • 2015: Investment by CA Lotus Investments in company.
  • 2015: Incorporation of subsidiary in Uganda.
  • 2015: Incorporation of branch office in Zambia.
  • 2017: Acquisition of Sanjeevani Pathology Laboratory in Rajkot.
  • 2018: 2018 Public-Private partnership agreement executed with National AIDS Control Organisation, Government of India.
  • 2018: Scheme of Amalgamation 2018.
  • 2018: Incorporation of subsidiary in Tanzania.
  • 2020: Metropolis Healthcare executes pact to acquire 51% stake in Shraddha Diagnostic Centre

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+0.28%
1 Week
-2.56%
1 Month
+1.45%
3 Month
+29.39%
6 Month
+38.50%
1 Year
+83.24%
2 Year
+193.33%
5 Year
7 years 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 18.77 26.16 36.47 30.38 30.17 27.33 30.07
Return on Capital Employed (%) 27.47 40.06 54.28 45.22 45.10 37.90 41.60
Return on Assets (%) 14.48 19.06 23.75 16.93 15.51 14.78 18.43

Balance Sheet View Details

Particulars 7 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Shh. Funds 361 265 323 415 419 524 707
Non Curr. Liab. 10 1 16 148 142 195 111
Curr. Liab. 75 105 152 233 241 210 240
Minority Int. 23 20 21 14 1 2 1
Equity & Liab. 468 391 512 810 803 930 1,059
Non Curr. Assets 167 166 227 367 381 492 415
Curr. Assets 302 225 285 443 422 438 645
Misc. Exp. not W/O
Total Assets 468 391 512 810 803 930 1,059

Profit Loss View Details

Particulars 7 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Net Sales 455 524 545 647 761 856 998
Other Income 6 22 26 8 8 9 12
Total Income 461 546 570 655 769 865 1,010
Total Expenditure -337 -388 -391 -469 -557 -619 -708
PBIDT 124 158 179 186 212 246 302
Interest -2 -2 -2 -4 -4 -13 -12
Depreciation -21 -21 -17 -19 -20 -39 -46
Taxation -33 -46 -53 -52 -63 -41 -61
Exceptional Items -8 -25
PAT 68 82 107 112 125 128 183

Cash Flow View Details

Particulars 5 years 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 102 104 90 215 249
Cash Fr. Inv. -86 2 35 -105 62
Cash Fr. Finan. -17 -87 -118 -55 -33
Net Change -1 19 7 55 278
Cash & Cash Eqvt 26 43 51 107 387

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 57.41 57.41 57.41 56.90 50.81 50.57 50.39 50.38 50.37
Public 42.59 42.59 42.59 43.10 49.19 49.43 49.61 49.62 49.63
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 45.29 45.29 33.83 33.83 37.85 5.44 5.44 3.30 3.30

Announcements View Details

Mon, 02 Aug 2021
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
We would like to inform you that Edelweiss Broking Limited will host an Earnings call on behalf of the Company with the analysts and investors at 5:30 p.m. (IST) on Friday August 6 2021 wherein the management of the Company will discuss the Financial and Operational Performance of Q1FY22.

This is for your information and appropriate dissemination.
Sat, 31 Jul 2021
Board Meeting Intimation for Intimation Of Board Meeting Scheduled To Be Held On Friday August 6 2021
Metropolis Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2021 inter alia to consider and approve the Unaudited Standalone & Consolidated Financial Results of the Company for the quarter ended June 30 2021;
Proposal for raising funds either by way of private placement or preferential issue or public issue or through any other permissible mode and/or combination thereof including by way of Qualified Institutions Placement in accordance with applicable laws; and other matters


Mon, 19 Jul 2021
Announcement under Regulation 30 (LODR)-Newspaper Publication
Copy of Newspaper Publication

Technical Scans View Details

Wed, 04 Aug 2021
Closing Above Previous High Closing Above Previous High
Close Within 52 Week High Zone Close Within 52 Week High Zone
Tue, 03 Aug 2021
Close Within 52 Week High Zone Close Within 52 Week High Zone
Increasing Relative Strength - Sectoral Index Increasing Relative Strength - Sectoral Index
MFI Trending Up MFI Trending Up

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 188,527.75 785.85 +0.0%
Divi's Laboratories Ltd. 131,785.24 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. 79,333.82 4,783.30 +0.2%
Cipla Ltd. 75,796.16 945.20 +0.6%
Cadila Healthcare Ltd. 60,170.47 584.80 -0.5%
Apollo Hospitals Enterprise Ltd. 58,468.59 4,075.50 +0.2%
Piramal Enterprises Ltd. 57,915.28 2,601.15 +2.0%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 31.40 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 66.41 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.66 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 31.52 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 28.20 584.80 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 388.86 4,075.50 +0.2%
Piramal Enterprises Ltd. Consolidated 2021-03 43.47 2,601.15 +2.0%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 3.94 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 14.18 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.44 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 4.15 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 4.63 584.80 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.72 4,075.50 +0.2%
Piramal Enterprises Ltd. Consolidated 2021-03 1.69 2,601.15 +2.0%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 0.10 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 584.80 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,075.50 +0.2%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 2,601.15 +2.0%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 14.13 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 584.80 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,075.50 +0.2%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 2,601.15 +2.0%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 17.85 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 584.80 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,075.50 +0.2%
Piramal Enterprises Ltd. Consolidated 2021-03 10.03 2,601.15 +2.0%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2020-03 6,969.40 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 19,159.59 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 584.80 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,075.50 +0.2%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 2,601.15 +2.0%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2020-03 1,984.29 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 2,401.30 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 584.80 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,075.50 +0.2%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 2,601.15 +2.0%